Novo Nordisk to restart liraglutide obesity studies (Reuters, 22 June 2010)

---

Danish Pharma company Novo Nordisk has announced plans to restart trials of its type-2 diabetes drug liraglutide to assess its potential use as an anti-obesity medication.

Full article